{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-028337","form_type":"8-K","ticker":"QTRX","cik":"0001503274","company_name":"Quanterix Corp","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.776323+00:00","generated_at":"2026-06-27T02:57:04.141318+00:00","sec_items":["2.02","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Quanterix Q4 rev +35% non-GAAP, CEO Hrusovsky becomes Exec Chair, Toloue CEO, Lilly deal $11M","bullets":["Q4 GAAP total revenue $30.3M (+16% YoY); non-GAAP total revenue $29.3M (+35% YoY).","FY 2021 GAAP total revenue $110.6M (+28% YoY); product revenue $81.1M (+84% YoY).","CEO Kevin Hrusovsky becomes Executive Chairman; President Masoud Toloue succeeds as CEO and joins Board, effective April 25, 2022.","Collaboration with Eli Lilly: non-exclusive license to P-tau217 antibody technology; Lilly funds $11M development this year."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-028337","json":"https://secwatch.observer/filing/0001104659-22-028337.json","markdown":"https://secwatch.observer/filing/0001104659-22-028337.md","text":"https://secwatch.observer/filing/0001104659-22-028337.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503274/000110465922028337/0001104659-22-028337-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503274/000110465922028337/tm226991d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:57:04.141318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e89c887540","claim":"Kevin Hrusovsky changed role as Executive Chairman at Quanterix Corp.","evidence_excerpt":"Effective April 25, 2022, Chairman and Chief Executive Officer Kevin Hrusovsky will become Executive Chairman of the Board of Directors, and President of Quanterix and Diagnostics Masoud Toloue will succeed Mr. Hrusovsky as Chief Executive Officer and join Quanterix’ Board of Directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503274/000110465922028337/0001104659-22-028337-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"become"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"},{"claim_id":"f89156d4d7","claim":"Masoud Toloue was appointed as Chief Executive Officer at Quanterix Corp.","evidence_excerpt":"and President of Quanterix and Diagnostics Masoud Toloue will succeed Mr. Hrusovsky as Chief Executive Officer and join Quanterix’ Board of Directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503274/000110465922028337/0001104659-22-028337-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"succeed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}